

IN THE CLAIMS:

The following Listing of Claims replaces all prior Listings, and versions, of claims in the above-identified patent application.

Listing of Claims

1-87. (Cancelled)

88. (New) An isolated antibody, antigen binding fragment, or binding partner, that selectively binds to at least one epitope of a protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9.

89. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 88, wherein said antibody selectively binds to an epitope of a protein consisting essentially of an amino acid sequence spanning from a starting position of one of amino acid residues from about 252-289 of SEQ ID NO:3 to an ending position of about amino acid residue 414 of SEQ ID NO:3.

90. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 88, wherein said antibody selectively binds to an epitope of a protein consisting essentially of an amino acid sequence spanning from a starting position of one of amino acid residues from about between 252-289 of SEQ ID NO:5 to an ending position of about amino acid residue 403 of SEQ ID NO:5.

91. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 88, wherein the antibody is a monoclonal antibody.

92. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 88, wherein the antibody is a genetically engineered antibody.

93. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 88, wherein the antibody is a bispecific antibody.

94. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 93, wherein the antibody binds to two different epitopes of said protein.

95. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 93, wherein the antibody comprises a first antigen binding portion that binds to the

epitope of a protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9; and a second portion that binds to a cell surface molecule expressed by a cell which expresses a PS receptor.

96. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 95, wherein the second portion binds a cell surface molecule on a target cell selected from the group consisting of a macrophage, a fibroblast, and an epithelial cell.

97. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 95, wherein the second portion binds a cell surface molecule on a tumor cell.

98. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 88, wherein the antigen binding fragment is an Fv, Fab, Fab', or F(ab)<sub>2</sub> fragment.

99. (New) The isolated antibody, antigen binding fragment, or binding partner of Claim 88, wherein the antibody is a single chain antibody.

100. (New) A composition, comprising the antibody, antigen binding fragment, or binding partner of Claim 88 and a pharmaceutically acceptable carrier.

101. (New) A method to stimulate or increase the activity of a phosphatidylserine receptor, comprising contacting a phosphatidylserine receptor with the antibody, antigen binding fragment, or binding partner of Claim 88, wherein the antibody, antigen binding fragment, or binding partner increases the activity of said phosphatidylserine receptor, and wherein said receptor comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9.

102. (New) The method of Claim 101, wherein the phosphatidylserine receptor is expressed by a dendritic cell or macrophage at a site of a graft.

103. (New) The method of Claim 101, wherein the phosphatidylserine receptor is expressed by a dendritic cell or macrophage at a site of inflammation.

104. (New) The method of Claim 101, wherein the phosphatidylserine receptor is expressed by a dendritic cell or macrophage at a site of an autoimmune response.

105. (New) A method to reduce the activity of a phosphatidylserine receptor, comprising contacting a phosphatidylserine receptor with the antibody, antigen binding fragment, or binding partner of Claim 88, wherein said the antibody, antigen binding

fragment, or binding partner decreases the activity of said phosphatidylserine receptor, and wherein said receptor comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9.

106. (New) The method of Claim 105, wherein said antibody selectively binds to said receptor and reduces the activity of said receptor.

107. (New) The method of Claim 105, wherein the phosphatidylserine receptor is expressed by a tumor cell.

108. (New) The method of Claim 105, wherein the phosphatidylserine receptor is expressed by a cell that is susceptible to infection by a parasite.

109. (New) The method of Claim 105, wherein the phosphatidylserine receptor is expressed by a cell that is susceptible to infection by a virus.